Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
MK-3586 is an investigational drug candidate being developed by Merck & Co. for the treatment of rheumatoid arthritis. In late 2026, a Phase I clinical trial (MK-3586-001) was authorized in Belgium to evaluate the safety, tolerability, and pharmacokinetics of MK-3586 in healthy participants. As an early-stage clinical asset, its specific molecular target and mechanism of action have not been publicly disclosed.
Beyond the preview
Go deeper on MK-3586.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-3586.